Uskent, NecdetAyla, SuleMandel, Nil MolinasOzkan, MetinTeomete, MehmetBaloglu, HuseyinAydincer, CenkYergok, HaleDogan, EnderBerk, BarkinYazar, Aziz2023-02-212023-02-212020-01-0110.1155/2020/1360431https://hdl.handle.net/11443/2521http://dx.doi.org/10.1155/2020/1360431Expression ofN-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, p<0.001). We propose that, regardless of staining intensity, the presence of NeuGcGM3 in patient tissues might be an indicator of benefit in Racotumomab treatment.ArticleWOS:000552809100002